Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis

Liver Transplantation

Volumn 17, Issue 8, 2011, Pages 905-913

  Saliba, Faouzi ^a   Dharancy, Sébastien ^b   Lorho, Richard ^c   Conti, Filoména ^d   Radenne, Sylvie ^e   Neau Cransac, Martine ^f   Hurtova, Monika ^g   Hardwigsen, Jean ^h   Calmus, Yvon ^d   Dumortier, Jérome ⁱ  

^a HÔPITAL PAUL BROUSSE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e CROIX ROUSSE HOSPITAL   (France)

^f HÔPITAL PELLEGRIN   (France)

^g HENRI MONDOR HOSPITAL   (France)

^h HÔPITAL DE LA CONCEPTION   (France)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CHOLESTEROL; CREATININE; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; TRIACYLGLYCEROL;

ACNE; ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; BACTERIAL INFECTION; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LEUKOCYTE COUNT; LEUKOPENIA; LIVER BIOPSY; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INFECTION;

ADULT; AGED; BIOPSY; CALCINEURIN; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 79960797525     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22292     Document Type: Article

References (49)

1. Vitko S, Tedesco H, Eris J, Pascual J, Whelchel J, Magee JC, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626-635. (Pubitemid 38523586)
2. Tedesco Silva H Jr, Cibrik D, Johnston T, Lackova E, Mange K, Panis C, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10: 1401-1413.
3. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377: 837-847.
4. Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008; 85: 821-826. (Pubitemid 351440746)
5. Salvadori M, Scolari MP, Bertoni E, Citterio F, Rigotti P, Cossu M, et al. Everolimus with very low-exposure cyclosporine A in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009; 88: 1194-1202.
6. Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010; 23: 1084-1093.
7. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P,; RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858. (Pubitemid 37025404)
8. Lehmkuhl HB, Arizon J, Viganó M, Almenar L, Gerosa G, Maccherini M, Varnous S, Musumeci F, Hexham JM, Mange KC, Livi U,; 2411 Study Investigators. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009; 88: 115-122.
9. Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH,. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010; 89: 864-872.
10. Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, et al. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. J Heart Lung Transplant 2008; 27: 197-202. (Pubitemid 351221047)
11. Potena L, Bianchi IG, Magnani G, Masetti M, Coccolo F, Fallani F, Russo A, Grigioni F, Branzi A, Ponticelli C,. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study. Transplantation 2010; 89: 263-265.
12. Gude E, Gullestad L, Arora S, Simonsen S, Hoel I, Hartmann A, et al. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. J Heart Lung Transplant 2010; 29: 641-647.
13. Holdaas H, Bentdal Ø, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K,. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008; 22: 366-371. (Pubitemid 351689669)
14. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD,. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565. (Pubitemid 39097102)
15. Filipponi F, De Carlis L, Metselaar HJ, Nevens F, Saliba F, Junge G,. Everolimus in de novo liver transplant recipients to either minimize or eliminate tacrolimus-study design and update [abstract]. Liver Transpl 2010; 16 (suppl 1): S132-S133.
16. Masetti M, Montalti R, Rompianesi G, Codeluppi M, Gerring R, Romano A, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010; 10: 2252-2262.
17. De Simone P, Carrai P, Precisi A, Petruccelli S, Baldoni L, Balzano E, et al. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int 2009; 22: 279-286.
18. Mártinez JM, Pulido LB, Bellido CB, Usero DD, Aguilar LT, Moreno JL, et al. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation. Transplant Proc 2010; 42: 641-643.
19. Alamo JM, Barrera L, Cadado MD, Bernal C, Marin LM, Suarez G, et al. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation. Transplant Proc 2009; 41: 2181-2183.
20. Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E,. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl 2009; 15: 1792-1797.
21. Gomez-Camarero J, Salcedo M, Rincon D, Lo Iacono O, Ripoll C, Hernando A, et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007; 84: 786-791. (Pubitemid 47480665)
22. Chiurchiu C, Carreño CA, Schiavelli R, Petrone H, Balaguer C, Trimarchi H, Pujol GS, Novoa P, Acosta F, González C, Arriola M, Massari PU,; Argentinian Registry of Everolimus Treated Renal Transplant Recipients. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies. Transplant Proc 2010; 42: 277-279.
23. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF,; Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
24. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
25. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P,; Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcomes measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit Care 2004; 8: R204-R212.
26. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM,. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940. (Pubitemid 37064766)
27. Karie-Guigues S, Janus N, Saliba F, Dumortier J, Duvoux C, Calmus Y, et al. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study. Liver Transpl 2009; 15: 1083-1091.
28. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH,. Renoprotection: one or many therapies? Kidney Int 2001; 59: 1211-1226. (Pubitemid 32281208)
29. De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009; 15: 1262-1269.
30. Gutiérrez-Dalmau A, Campistol JM,. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant 2007; 22 (suppl 1): i11-i16. (Pubitemid 47073739)
31. Monaco AP,. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009; 87: 157-163.
32. Treiber G,. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther 2009; 9: 247-261.
33. Koehl GE, Schlitt HJ, Geissler ETK,. Rapamycin and tumor growth: mechanisms behind its anticancer activity. Transplant Rev 2005; 19: 20-31. (Pubitemid 40542873)
34. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135. (Pubitemid 34155123)
35. Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W, Shaw L, Wasik MA,. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710-1717. (Pubitemid 36629155)
36. Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 2000; 97: 4285-4290. (Pubitemid 30226125)
37. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601. (Pubitemid 38796850)
38. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M,. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73: 1565-1572. (Pubitemid 34568667)
39. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A,; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
40. Hainsworth JD, Spigel DR, Burris HA III, Waterhouse D, Clark BL, Whorf R,. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010; 28: 2131-2136.
41. Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010; 28: 1904-1910.
42. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85: 320-324.
43. Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28: 1408-1414.
44. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28: 69-76.
45. Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15: 1834-1842.
46. Zimmermann MA, Trotter FJ, Wachs M, Bak T, Campsen J, Skibba A, Kam I,. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14: 633-638. (Pubitemid 351696274)
47. Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010; 89: 227-231.
48. Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, Tang ZY, Fan J,. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008; 40: 3548-3553.
49. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM,. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-1243.